Personalizing Your Approach Individual responses to nutrition timing can vary based on factors like body composition, training experience, and metabolic health
However, the existing research provides compelling evidence for their anti-inflammatory potential and represents an exciting frontier where rigorous clinical research can validate what many practitioners are already observing in clinical practice
It also flags a history of small-bowel obstruction or fistulizing disease as a reason to speak with a gastroenterologist first, since slowed gastric emptying and reduced motility may create mechanical risk
Hydrating Agents: Maintain skin moisture during cleansing
The newest GLP-1 drug, tirzepatide, was first approved in 2022 as Mounjaro for treatment of diabetes and later approved in 2024 as Zepbound for obesity
Individuals with a body mass index (BMI) over 30 are eligible for GLP-1s, as are individuals with a lower BMI and a qualifying chronic condition